Hidden costs in breast cancer-related lymphedema
Autor/a
Masia, Jaume
Carlos, G. Forero
Fuster, Pilar
Fecha de publicación
2021ISSN
0749-2081
Resumen
Breast cancer is the most common neoplastic process in women, with an incidence of 2,088,849 cases in 2018, and an overall 5-year survival of 90% and a 10-year survival of 83%.1 Lymphedema secondary to breast cancer treatment can be an extremely serious and functionally limiting complication.2 With five times more risk of hospital admission for continuous infections (lymphangitis or cellulitis) than patients without this condition3 and where the effect on the quality of life4 and professional careers5 of women is clearly altered. Evidence from a meta-analysis estimates that breast cancer-related lymphedema has an annual incidence of 21% in patients with axillary clearance, affecting up to 295,320 women/year, with 140 to 250 million prevalent cases.
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
Inglés
Materias (CDU)
616 - Patología. Medicina clínica. Oncología
Palabras clave
Cáncer de mama
Linfedema
Càncer de mama
Limfedema
Breast cancer
Lymphedema
Páginas
Desconocido
Publicado por
Elsevier
Colección
37;2
Publicado en
Elsevier
Citación
Martínez-Jaimez, Patricia; Masia, Jaume; Carlos, G. Forero [et al.]. Hidden costs in breast cancer-related lymphedema. Seminars in Oncology Nursing, 37(2), 151118. Disponible en: <https://www.sciencedirect.com/science/article/abs/pii/S0749208121000012?via%3Dihub>. Fecha de acceso: 11 mar. 2024. DOI: 10.1016/j.soncn.2021.151118
Este ítem aparece en la(s) siguiente(s) colección(ones)
- Ciències de la Salut [725]
Derechos
© 2021 Elsevier Inc. All rights reserved.